Immunotherapy Effective Against Stomach Cancer
By Dennis Thompson HealthDay Reporter
FRIDAY, June 6, 2025 — Immunotherapy combined with chemo can give people a fighting chance against stomach and esophageal cancers, a new clinical trial says.
People treated with durvalumab and chemotherapy were much more likely to go into remission, according to clinical trial results published June 1 in The New England Journal of Medicine.
“This is a major step forward for patients facing this difficult diagnosis,” lead researcher Dr. Yelena Janjigian, chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, said in a news release.
“To be able to tell a patient that their cancer has completely responded to treatment — and that they are cured — is one of the most rewarding moments in oncology,” Janjigian said. “These results bring us closer to making that outcome a reality for many more patients worldwide.”
Durvalumab is an IV drug that boosts the immune system’s ability to detect and kill cancer cells. It’s used to treat a range of cancers, including those of the lung, bile duct, gall bladder, endometrium and bladder, according to Drugs.com.
Surgery and chemotherapy are the current standard of care, but stomach and esophageal cancers remain some of the deadliest worldwide, researchers said in background notes.
Cure rates are low — around 40% — and most patients who relapse do so within three years of surgery, researchers said. Less than half of patients are alive at five years.
For this trial, 474 people with stomach or esophageal cancer were randomly assigned to take either durvalumab or a placebo alongside the standard chemotherapy brew used to treat these cancers.
About 19% of those taking durvalumab had no remaining cancer detected at surgery, compared with 7% of those taking placebo, results show.
After two years, 67% of those given durvalumab were alive without any indication of cancer progression, compared to 58% of those given a placebo, researchers found.
Adding durvalumab to chemo didn’t delay either surgery or recovery, researchers said, and the rate of serious side effects was about the same between the two groups.
The new study was funded by AstraZeneca, the maker of durvalumab.
Sources
- Memorial Sloan Kettering Cancer Center, news release, June 1, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
NIH to Fund $10M in Long-Term Health Studies After Ohio Train Disaster
MONDAY, June 23, 2025 — The National Institutes of Health (NIH) will fund studies of the long-term health effects of a 2023 Ohio train derailment that released more than 1...
Appendix Cancer Cases Surge in Millennials and Gen X
TUESDAY, June 17, 2025 — When Chris Williams started feeling sharp stomach pain one night in 2021, he went straight to the emergency room. The next morning, he had surgery...
Blood Tests Can Detect Cancer Years Earlier
TUESDAY, June 10, 2025 — Blood tests can detect evidence of cancer three years earlier than the disease would otherwise be diagnosed, a new small-scale pilot study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.